Compassionate Use: Progressive Metastatic Castrate Resistant Prostate Cancer; Monotherapy Treatment With Trametinib

NCT03386071 · clinicaltrials.gov ↗

NO_LONGER_AVAILABLE

Status

OTHER

Sponsor class

Conditions

Progressive Metastatic Castrate Resistant Prostate Cancer

Interventions

DRUG: Trametinib 2 mg

Sponsor

Jonsson Comprehensive Cancer Center

Collaborators

[object Object]